COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE

被引：0
|
作者：
El Ouagari, K. [1 ]
Pawar, V [2 ]
Coombs, J. [3 ]
Rubin, J. [2 ]
机构：
[1] Novartis Pharmaceut Canada, Dorval, PQ, Canada
[2] I3 Innovus, Medford, MA USA
[3] Novartis, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A270 / A270
页数：1
相关论文
共 50 条
  • [21] Adjuvant and down-staging treatment with imatinib in gastrointestinal stromal tumors
    Nilsson, B.
    Andersson, A.
    Ahlman, H.
    JOURNAL OF SURGICAL ONCOLOGY, 2008, 98 (03) : 145 - 146
  • [22] Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
    Reichardt, P.
    Blay, J. -Y.
    Gelderblom, H.
    Schlemmer, M.
    Demetri, G. D.
    Bui-Nguyen, B.
    McArthur, G. A.
    Yazji, S.
    Hsu, Y.
    Galetic, I.
    Rutkowski, P.
    ANNALS OF ONCOLOGY, 2012, 23 (07) : 1680 - 1687
  • [23] Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?
    Peter Hohenberger
    Nature Clinical Practice Oncology, 2008, 5 : 240 - 241
  • [24] Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?
    Hohenberger, Peter
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (05): : 240 - 241
  • [25] Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
    Sutton, Thomas L.
    Billingsley, Kevin G.
    Johnson, Alicia J.
    Corless, Christopher L.
    Blanke, Charles D.
    Heinrich, Michael C.
    Mayo, Skye C.
    JOURNAL OF SURGICAL ONCOLOGY, 2024, 130 (01) : 40 - 46
  • [26] Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST).
    Molimard, M.
    Bouchet, S.
    Poulette, S.
    Chauzit, E.
    Titier, K.
    Moore, N.
    Lassalle, R.
    Abouelfath, A.
    Italiano, A.
    Chevreau, C.
    Duffaud, F.
    Rios, M.
    Cupissol, D.
    Adenis, A.
    Ray-Coquard, I. L.
    Bouche, O.
    Le Cesne, A.
    Blay, J.
    Nguyen, B. Bui
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Cost-Effectiveness of Ruxolitinib Versus Best-Available Therapy for Medical Treatment of Myelofibrosis: Canadian Societal Perspective
    El Ouagari, Khalid
    Knight, Christopher John
    Mendelson, Estella T.
    BLOOD, 2012, 120 (21)
  • [28] Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis
    Farid, Mohamad
    Ong, Johnny
    Chia, Claramae
    Tan, Grace
    Teo, Melissa
    Quek, Richard
    Teh, Jonathan
    Matchar, David
    CLINICAL SARCOMA RESEARCH, 2020, 10 (01)
  • [29] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain
    Maroto, P.
    Villavicencio, H.
    Pinol, C.
    Urruticoechea, L.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
  • [30] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma.
    Gao, X.
    Reddy, P.
    Dhanda, R.
    Gondek, K.
    Yeh, Y. C.
    Stadler, W. M.
    Jonasch, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
12345